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Fibrinogen-to-albumin ratio predicts mortality in COVID-19 
patients admitted to the intensive care unit
Abstract
Introduction: Coronavirus disease 2019 (COVID-19) is an inflammatory disease, and serum albumin and fibrinogen are two im-
portant factors in systemic inflammation. We aimed to investigate the relationship between the fibrinogen-to-albumin ratio (FAR) 
and in-hospital mortality in COVID-19 patients admitted to the intensive care unit (ICU). 
Material and methods: Patients diagnosed with COVID-19 admitted to the Adiyaman Training and Research Hospital from August 
to November 2020 were enrolled in this retrospective cohort study. They were divided into 2 groups based on in-hospital mortality: 
a survivor group (n = 188) and a non-survivor group (n = 198). FAR was calculated by dividing the fibrinogen value by the albumin 
value. Mortality outcomes were followed up until December 15, 2020.
Results: The average age of the patients was 71.2 ± 12.9 years, and 54% were male. On multivariate logistic analysis, diabetes 
mellitus (OR: 1.806; 95% CI: 1.142–2.856; p = 0.011), troponin I levels (OR: 1.776; 95% CI: 1.031–3.061; p = 0.038), and FAR 
(OR: 1.004; 95% CI: 1.004–1.007; p = 0.010) at ICU admission were independent predictors of in-hospital mortality in patients 
with COVID-19.
Conclusions: The FAR at admission was associated with mortality in patients infected with SARS-CoV-2 in the ICU.
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Introduction
Severe respiratory distress syndrome caused 
by coronavirus-2 (SARS-CoV-2) has affected the 
whole world in terms of health, social, education-
al, and economic aspects. The main cause of mor-
bidity and mortality in patients with COVID-19 is 
viral pneumonia leading to acute respiratory 
distress syndrome [1]. In COVID-19 patients, 
D-dimer, troponin, procalcitonin, ferritin, and 
fibrinogen levels progressively increase in parallel 
with disease severity, while lymphocyte counts 
and albumin levels gradually decrease. A throm-
boembolic state, thrombo-inflammation, and 
coagulopathy have been suggested to play pivotal 
roles in the severity of clinical deterioriation in 
COVID-19 patients [2].
Fibrinogen is a positive acute phase reactant 
secreted from the liver, and it plays an active role 
in both the coagulation cascade and inflamma-
tion. Its synthesis increases in both acute and 
chronic inflammation as well as cardiovascular 
diseases and malignancy. Fibrinogen stimulates 
the production of proinflammatory cytokines 
such as interleukins-1β, IL-6 and tumor necrosis 
factor alpha [3]. In clot formation, fibrinogen is 
converted to fibrin by the enzyme thrombin; it 
also increases blood viscosity and stimulates 
thrombocyte aggregation. 
Albumin, a major plasma protein, is a neg-
ative acute phase reactant, and its plasma level 
decreases in inflammatory diseases. Low albumin 
levels in hospitalized patients at the time of ad-
mission are associated with increased short- and 
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long-term mortality rates [4]. Previous studies 
have shown significant associations of hypoalbu-
minemia with increased cardiovascular morbidity 
and mortality [5, 6].
Recent studies have also shown that the 
fibrinogen-to-albumin ratio (FAR) is associated 
with poor clinical outcomes in patients with 
cardiovascular diseases characterized by inflam-
mation and thrombosis, and in those with ma-
lignancies [7, 8]. In addition, the FAR is an inde-
pendent risk factor predicting disease severity in 
COVID-19 [9]. A meta-analysis investigating the 
mortality of patients with COVID-19 admitted to 
the intensive care unit (ICU) has been published. 
It included 52 studies published up to 30 Sep-
tember 2020; mortality rates varied from 10.6% 
to 61.9% depending on the geographical region 
[10]. It is important to predict the mortality of 
patients with COVID-19 requiring ICU treatment. 
Therefore, this study investigated the potential 
association between the FAR and in-hospital mor-




We retrospectively analyzed the data of pa-
tients with COVID-19 treated in the Adiyaman 
University Education and Research Hospital ICU 
between 1 August and 30 November, 2020. Pa-
tients attending the hospital who presented with 
cough, dyspnea, myalgia, malaise, weight loss, 
sore throat, headache, fever, loss of appetite, 
diarrhea, nausea, vomiting, rhinitis, and/or loss 
of smell received the polymerase chain reaction 
(PCR) test for SARS-CoV-2 using nasopharyngeal 
swab specimens. Those with positive PCR results 
and with severe SARS-CoV-2 pneumonia were 
included in the study. Patients with a negative 
PCR result, lack of appropriate laboratory test 
parameters, terminal malignancy, or who were 
< 18 years of age were excluded. 
The diagnosis of SARS-CoV-2 pneumonia 
was made according to the World Health Or-
ganization interim guidelines. Patients with 
COVID-19 who had dyspnea, respiratory rate > 
30/min, tachycardia > 100/min, blood oxygen 
saturation level < 90% despite 5 L/min oxygen 
treatment, ratio of the partial pressure of arteri-
al oxygen to the fraction of inspired oxygen of 
< 300 mm Hg, infiltrates in > 50% of the lung 
fields on X-rays, need for mechanical ventilation, 
development of acute organ dysfunction, sepsis, 
septic shock, immunosuppression, acute bleeding 
diathesis, arrhythmia, or increased troponin level 
were admitted to the ICU [11, 12]. 
Demographic characteristics, laboratory 
parameters, comorbidities (cardiovascular dis-
eases, cerebrovascular diseases, hypertension, 
diabetes mellitus [DM], chronic obstructive lung 
disease, chronic kidney disease, or prior malig-
nancy), epidemiologic features, and treatment 
protocols of patients were collected from the 
electronic medical records of our hospital. The 
endpoints of the study were discharge from the 
ICU and/or in-hospital mortality. Patients were 
divided into two groups according to in-hospi-
tal mortality: survivors and non-survivors. The 
patients discharged from the hospital were 
followed-up with until 15 December 2020 to 
determine mortality. 
Collection of blood samples 
and biochemical analysis
Blood samples were collected for hemato-
logical and biochemical testing within 24 h after 
admission to the ICU. Complete white blood cell 
counts, including neutrophil and lymphocyte 
counts, were measured using an automated 
hematologic analyzer (CELL-DYN Ruby, Abbott 
Diagnostics, Abbott Park, IL, USA) and are ex-
pressed as × 1,000 cells/mm3. The hemoglobin 
level and platelet count were also measured. 
Glucose, creatinine, aspartate aminotransferase, 
alanine aminotransferase, lactate dehydrogenase, 
albumin, sodium, potassium, calcium, ferritin, 
and C-reactive protein (CRP) levels were analyzed 
by the Architect c8000 Chemistry System (Ab-
bott Diagnostics) using commercial kits (Abbott 
Diagnostics). 
Troponin I and D-dimer levels were analyzed 
using an immunoassay analyzer (Radiometer 
AQT90 FLEX, Radiometer Medical ApS, Brønshøj, 
Denmark). The activated partial thromboplastin 
time (aPTT), prothrombin time, international 
standardized ratio, and plasma fibrinogen concen-
tration were measured using an automatic coagu-
lation analyzer (STA Compact, Diagnostica Stago, 
Parsippany, NJ, USA). FAR was calculated using the 
SPSS statistical program by dividing the fibrino-
gen concentration by the albumin concentration. 
Myocardial injury was diagnosed if the serum 
concentration of troponin I was > 99th percentile 
of the upper reference limit (> 0.023 ng/mL), as 
measured by our hospital laboratory.
The study procedures complied with the 
Declaration of Helsinki. The Ministry of Health 
and Adiyaman University Ethics Committee on 
Human Research approved the study protocol.
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Statistical analysis
Data were examined using SPSS software 
17.0 for Windows (Armonk, NY, USA). The Kolm-
ogorov-Smirnov test was used to determine the 
presence of a normal distribution of continuous 
variables. Variables with a normal distribution 
are expressed as means ± standard deviation, 
whereas those with a non-normal distribution 
are expressed as medians with interquartile 
ranges. Categorical variables are expressed as per-
centages. Group differences were assessed using 
the Student’s unpaired t-test or the Mann–Whit-
ney U test. Differences in categorical variables 
were assessed using the Pearson chi-square and 
Fisher exact tests, depending on the sample size. 
Pearson’s and Spearman’s tests were used for 
correlation analyses. Forward variable selection 
was applied to the binary logistic regression 
analysis to eliminate statistically non-significant 
predictors. The Hosmer-Lemeshow test was used 
to evaluate model fit. The odds ratio (OR) and 
95% confidence interval (CI) were calculated for 
each independent variable. A p-value < 0.05 was 
considered significant.
Results
The data of 838 COVID-19 patients treated 
in the ICU were analyzed retrospectively. Those 
with a negative PCR test (n = 320), a lack of 
appropriate laboratory parameters (n = 122), or 
terminal malignancy (n = 10) were excluded from 
the study. After exclusion, 386 patients (209 [54%] 
males, aged 71.2 ± 12.9 years) were included in 
this retrospective cohort study. The in-hospital 
mortality rate was 51.3%.
The demographic characteristics and co-
morbid conditions are shown in Table 1. The 
study groups included surviving (n = 188) 
and non-surviving (n = 198) COVID-19 pa-
tients. There were no significant differences 
between the groups in terms of age or sex. The 
rate of DM (p = 0.003), chronic kidney disease 
(p = 0.012), and duration of hospital stay (p < 
0.001) were higher in the non-survivor group 
compared with the survivors.
The laboratory parameters and treatments 
are shown in Table 2 according to the study 
groups. White blood cell and neutrophil counts 
were higher, while the lymphocyte count was 
lower in the non-survivor group when compared 
with the survivors; however, these differences 
were not statistically significant. The FAR, neutro-
phil-to-lymphocyte ratio, prothrombin time, in-
ternational standardized ratio, levels of CRP, glu-
cose, creatine, urea, aspartate aminotransferase, 
lactate dehydrogenase, fibrinogen, procalcitonin, 
ferritin, D-dimer, and troponin I were higher in 
the non-surviving group when compared with 
surviving COVID-19 patients (all, p < 0.05). In 
contrast, the platelet count (p = 0.047) and albu-
min level (p = 0.004) were higher in the survivor 






Male, n (%) 94 (50) 115 (58) 0.111a
Age [years] 70.7 ± 13.8 71.7 ± 13.8 0.439b
Smoking, n (%) 72 (38) 85 (42) 0.355a
Heart failure, n (%) 21 (11) 30 (15) 0.240a
Hypertension, n (%) 101 (53) 122 (62) 0.117a
Coronary artery disease, n (%) 84 (44) 85 (43) 0.546a
Cerebrovascular disease, n (%) 20 (11) 19 (8) 0.388a
Diabetes mellitus, n (%) 58 (31) 75 (46) 0.003a
Chronic lung disease, n (%)* 61 (32) 59 (30) 0.574a
Malignancy, n (%) 12 (6) 10 (5) 0.572a
Chronic kidney disease, n (%) 14 (7) 31 (16) 0.012a
Length of intensive care unit stay [days] 4 (2.3–7.7) 8 (3–14) < 0.001c
aDepending on the Expected count, Pearson Chi-Square or Fisher Exact test was used. Descriptive statistics were presented as a number (%). 
bStudent’s unpaired t-test was used. Descriptive statistics were presented as mean ± standard deviation.
cMann–Whitney U test was used. Descriptive statistics were presented as median [IQR]. 
IQR — Interquartile range.
*Chronic lung disease was defined as chronic obstructive pulmonary disease, asthma, or chronic bronchitis
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group. The use of antiplatelet medications was 
greater in the non-survivor group.
The correlation analyses between the FAR 
and laboratory parameters is shown in Table 3. 
The FAR was positively correlated with the lev-
els of CRP (r = 0.447; p < 0.001), procalcitonin 
(r = 0.195; p < 0.001) and troponin I (r = 0.204; 
p < 0.001) (Figure 1). Logistic regression analysis 
was performed to determine the independent 
predictors of in-hospital mortality. The analy-
sis demonstrated that DM (OR: 1.806; 95% CI: 
1.142–2.856; p = 0.011), troponin I level (OR: 
Table 2. Laboratory findings and treatments of patients with SARS-CoV-2 pneumonia on admission to the intensive care 






Haemoglobin, [g/dL] 12.1 ± 2.1 12.1 ± 2.3 0.569b
Platelet count (× 103/µL) 233 (172–303) 207 (158–273) 0.047c
White blood cell count (× 103/µL) 9.5 (6.3–14) 10 (7.1–14) 0.089c
   Neutrophil count (× 103/µL) 7.5 (4.7–11.6) 8.3 (5.6–11.7) 0.072c
   Lymphocyte count (× 103/µL) 1.0 (0.6–1.4) 0.9 (0.7–1.4) 0.725c
NLR 7.1 (4.5–12) 8.6 (6.1–12.4) 0.014c
Glucose [mg/dL]  141 (106–195) 166 (117–234) 0.009c
Serum creatinine [mg/dL] 0.8 (1.1–0.7) 1.1 (0.8–1.8) < 0.001c
Urea [mg/dL] 46 (36–70) 63 (43–106) < 0.001c
Alanine aminotransferase [U/L] 24 (16–37) 24 (17–42) 0.498c
Aspartate aminotransferase [U/L] 35 (23–54) 43 (27–65) 0.005c
Lactate dehydrogenase [U/L] 408 (324–483) 532 (418–678) < 0.001c
Albumin [g/dL] 2.8 ± 0.5 2.6 ± 0.5 0.004b
Fibrinogen [g/L] 543.3 ± 164.8 595.6 ± 164.6 0.002b
FAR 206.8 ± 83.4 244.2 ± 98.1 < 0.001b
Serum potassium [mmol/L] 4.5 ± 0.7 4.6 ± 0.9 0.059b
Serum sodium [mmol/L] 136.1 ± 10.1 136.9 ± 7.7 0.446b
CRP [mg/dL] 9 (5–15) 14 (8–20) < 0.001c
Ferritin [ng/mL] 389 (234–604) 456 (286–729) 0.021c
Procalcitonin [ug/L] 0.21 (0.12–0.69) 0.64 (0.21–1.62) < 0.001c
D-dimer [µg/L] 1340 (784–2100) 1485 (911–3027) 0.017c
Troponin I [µg/L] 0.01(0.01–0.03) 0.01(0.01–0.22) < 0.001c
Activated partial thromboplastin time [s] 32 (28–36) 33 (28–38) 0.543a
Prothrombin time [s] 16 (14–18) 17 (15–19) 0.008c
International standardized ratio 1.2 (1.1–1.3) 1.2 (1.1–1.4) 0.036c
Mechanical ventilation, n (%) 15 (8) 165 (83) < 0.001a
Treatments, n (%)
   Antiviral agents 178 (95) 184 (93) 0.476a
   Antibacterial agents 187 (99) 195 (98) 0.328a
   Glucocorticoids 182 (97) 190 (96) 0.656a
   Anticoagulants 180 (96) 188 (95) 0.711a
   Antiplatelets 105 (56) 130 (66) 0.048a
   Convalescent plasma 85 (45) 95 (52) 0.586a
aDepending on the Expected count, Pearson Chi-Square or Fisher Exact test was used. Descriptive statistics were presented as a number (%). 
bStudent’s unpaired t-test was used. Descriptive statistics were presented as mean ± standard deviation.
cMann–Whitney U test was used. Descriptive statistics were presented as median [IQR]. 
CRP — C-reactive protein; FAR — fibrinogen-to-albumin ratio; IQR — interquartile range; NLR — neutrophil-to-lymphocyte ratio
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1.776; 95% CI: 1.031–3.061; p = 0.038), and FAR 
(OR: 1.004; 95% CI: 1.004–1.007; p = 0.010) at 
ICU admission were independent predictors 
of in-hospital mortality in patients with severe 
COVID-19 (Table 4).
Discussion
We evaluated the association between in-hos-
pital mortality and the FAR, calculated based on 
the laboratory parameters obtained from blood 
samples collected within 24 h of ICU admission. 
The FAR was higher in the non-survivor group 
and was an independent predictor of in-hospital 
mortality. Similar to other studies investigating 
the prognostic risk factors for COVID-19, our 
results showed that DM and an increased tropo-
nin I level were also independent predictors of 
in-hospital mortality.
Fibrinogen, also known as Factor I, is a glyco-
peptide composed of three pairs of polypeptides 
covalently linked by disulfide bonds. Fibrino-
gen plays a major role in platelet aggregation 
via enzymatic conversion to fibrin and is also 
the main determinant of plasma viscosity and 
erythrocyte aggregation [13]. Several studies and 
meta-analyses have investigated the association 
between the fibrinogen level and cardiovascular 
diseases [14, 15]. Fibrinogen was found to be an 
independent risk factor for cardiovascular disease 
in these studies.
COVID-19 is characterized by respiratory 
failure, endothelial dysfunction, and activation 
of the coagulation pathway [16]. Patients with 
severe COVID-19 are susceptible to coagulation as 
a result of increased levels of coagulation factors 
Table 3. Correlation between the FAR and laboratory 
parameters
R P-value
CRP 0.447 < 0.001
Lactate dehydrogenase 0.052 0.277
Procalcitonin 0.195 < 0.001
Troponin I 0.204 < 0.001
NLR 0.098 0.054
CRP — C-reactive protein; FAR — fibrinogen-to-albumin ratio; NLR — neutro-
phil-to-lymphocyte ratio
Figure 1. Scatter plot image of the correlation between fibrinogen-to-albumin ratio and C-reactive protein in patients with COVID-19 (n = 386)
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Table 4. Multivariate logistic regression analyses of in-hospital mortality
Odds ratio 95% CI P-value
NLR 0.986 0.960–1.012 0.293
FAR 1.004 1.001–1.007 0.010
Age [years] 0.999 0.982–1.017 0.943
Sex, male 1.311 0.799–1.000 0.285
Diabetes mellitus 1.806 1.142–2.856 0.011
Hypertension 1.282 0.808–2.035 0.292
Procalcitonin [µg/L] 1.087 0.982–1.202 0.740
Smoking 1.017 0.623–1.660 0.946
D-dimer [µg/L] 1.000 1.000–1.000 0.968
Chronic kidney disease 1.364 0.644–2.889 0.448
Troponin I [µg/L] 1.776 1.031–3.061 0.038
Platelet counts (×103/µL) 0.998 0.996–1.000 0.093
CI — confidence interval; CRP — C-reactive protein; FAR — fibrinogen-to-albumin ratio; NLR — neutrophil-to-lymphocyte ratio
including fibrinogen, tissue factor, and Factor 7, 
a decrease in tissue plasminogen activator activi-
ty, and inhibition of the fibrinolytic pathway due 
to hypoxia, endothelial dysfunction, and hyper-
inflammation [17]. This leads to major venous 
thromboembolic events and arterial thrombosis 
[18] and is associated with a poor prognosis [19]. 
Thromboembolic events and in-situ thrombosis 
seem to contribute to multisystem injury, multior-
gan failure, and mortality in patients with SARS-
CoV-2 infection [20]. Increased D-dimer and 
fibrinogen levels together with prolongation of 
the aPTT promote coagulopathy in COVID-19 pa-
tients [21]. Increased levels of D-dimer, aPTT, and 
fibrinogen were associated with a poor prognosis 
in hospitalized patients with COVID-19 [22]. In 
our study, we observed that fibrinogen and D-di-
mer levels were higher in the non-survivor group 
when compared with the survivor group. 
Albumin has anticoagulant and antiplatelet 
activities, probably due to its antioxidant effect 
[23]. Albumin increases fibrinolysis and inhibites 
erythrocyte aggregation. In addition, albumin 
neutralizes fibrinogen binding to endothelial cells, 
thus antagonizing several prothrombotic effects 
of fibrinogen [24]. Also, endothelial dysfunction 
and blood viscosity are increased in hypoalbu-
minemia [25]. During inflammatory states, the co-
agulation cascade favors thrombus formation due 
to decreased synthesis and increased catabolism 
of albumin. Lower albumin levels were observed 
in patients with severe COVID-19 compared with 
non-severe COVID-19 in a meta-analysis [26]. 
A serum albumin level < 3.5 g/dL is associated 
with a higher mortality rate in COVID-19 patients 
[27]. In our study, the serum albumin level was 
< 3.5 g/dL in both groups but was significantly 
lower in the non-survivor group. In a study of 
299 COVID-19 patients, Huang et al. [28] showed 
a lower albumin level in the non-survivor group 
compared with the survivors, and hypoalbumin-
emia was a predictor of mortality regardless of age 
and comorbidities. Violi et al. [29] suggested that 
hypoalbuminemia may be related to hypercoag-
ulability in patients with severe SARS-CoV-2 in-
fection and found lower serum albumin levels 
in patients with ischemic events compared with 
thrombotic event-free patients with COVID-19. 
The FAR has been introduced as a new 
prognostic marker based on inflammation. The 
association between FAR and mortality has been 
investigated because inflammation has an import-
ant role in the pathogenesis of both malignancy 
and cardiovascular disease. FAR was shown to be 
associated with a poor prognosis in these diseases 
[7, 8]. There are limited data in the literature on 
the associations among the FAR, disease progres-
sion, and mortality in COVID-19 patients. Bi et 
al. [30] investigated the associations among the 
FAR, platelet count, and disease severity in 91 pa-
tients with non-severe COVID-19 and 21 patients 
with severe COVID-19. They suggested that the 
FAR and platelet count were independent pre-
dictors of the development of severe illness in 
SARS-CoV-2 infection. To date, no studies have 
investigated the association between the FAR and 
mortality in COVID-19 patients. In our study, 
we have proven that the FAR is an independent 
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predictor of mortality in patients with severe 
COVID-19 in the ICU. The significant association 
between elevated fibrinogen/low albumin levels 
and mortality in COVID-19 patients found in our 
study supports the role of the FAR in the patho-
physiology of the disease and the intensity of the 
thromboembolic and thrombotic state. FAR may 
be a useful and cost-effective parameter to pre-
dict in-hospital mortality in patients with severe 
SARS-CoV-2 infection.
Study limitations
As this was a retrospective, observational, 
and single-center study, our findings may not 
be generalizable. There were no ischemic/em-
bolic events recorded in our study population. 
Fibrinogen and albumin levels were measured 
within 24 h of hospitalization, and serial mea-
surements were not performed. All patients were 
administered low-molecular-weight heparin as 
an anticoagulant. Unfortunately, we were not 
able to measure plasma antifactor Xa activity, 
which is deemed to be the most accurate marker 
for monitoring therapeutic dosing of low-molec-
ular-weight heparin. 
Conclusions
We showed that the FAR, a novel inflam-
mation-based prognostic parameter, was higher 
in non-surviving patients when compared with 
surviving COVID-19 patients. In addition, the FAR 
was associated with mortality in patients infected 
with SARS-CoV-2 in the ICU. An increased FAR 
(as an indicator of the inflammatory and throm-
botic burden) might allow for early identification 
of COVID-19 patients at severe risk, which could 
assist in immediate optimization of the medical 
management of this highly susceptible group.
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